Английская Википедия:Centanafadine

Материал из Онлайн справочника
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Cs1 config Шаблон:Drugbox

Centanafadine [1]
Site IC50 (nM) Action Ref
Шаблон:Abbrlink 83 nM Blocker [1]
Шаблон:Abbrlink 6 nM Blocker [1]
Шаблон:Abbrlink 38 nM Blocker [1]

Centanafadine (INN) (former developmental code name EB-1020) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) that began its development with Euthymics Bioscience after they acquired DOV Pharmaceutical. It was developed as a treatment for attention-deficit hyperactivity disorder (ADHD) and inhibits the reuptake of norepinephrine, dopamine, and serotonin with a ratio of 1:6:14, respectively.[1][2][3][4] In 2011, Euthymics Bioscience spun off its development of centanafadine to a new company called Neurovance.[5][6] In March 2017, Otsuka Pharmaceutical acquired Neurovance and the rights to centanafadine.[7] As of January 2018, Otsuka's pipeline indicates it is in Phase II and III clinical trials for a number of different applications to medical conditions.[8][9][10]

See also

References

Шаблон:Reflist

External links

Шаблон:Monoamine reuptake inhibitors

Шаблон:Nervous-system-drug-stub